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ABSTRACT            
Elongating axons require a host of macromolecules for outgrowth. The importance of lipid, 
protein, and general RNA synthesis for initial axonal growth has been previously investigated, 
but the role of rRNA synthesis and ribosome production in axonal morphogenesis remains 
unclear. Therefore, rat hippocampal neurons were cultured and transfected with shRNA against 
either TIF-IA (the activator of RNA polymerase I) or RPS6 (a small ribosomal subunit 
component) to determine the effects of impaired de novo ribosome synthesis on axonal 
development during the first three days after plating. Our data show that shRPS6 weakly 
inhibited total axon length, but not longest axon path or number of axonal branches; shTIF-IA 
showed no significant inhibitory effect in all three parameters. Thus, these results indicate that 
the pre-existing ribosome supply was at least temporarily sufficient for growth during this initial 
phase of axonal development. 
 
BACKGROUND            
Known as the cellular “ribosome factory”, the nucleolus is the dynamic sub-nuclear structure in 
all eukaryotic cells. The nucleolus is composed of RNA and proteins grouped around specific 
chromosomal regions called nucleolar organizing regions (NORs), which are comprised of 
numerous tandem repeats of the ribosomal DNA (rDNA) coding for ribosomal RNA (rRNA) [1]. 
Primarily involved in ribosomal biogenesis, the nucleolus directs the synthesis and processing of 
rRNAs before assembling them together with ribosomal proteins (RPs) imported from the 
cytoplasm to create the large 60S and small 40S ribosomal subunits found in eukaryotic 
ribosomes [2]. Following production in the nucleolus and maturation in the nucleus, the large 
60S and small 40S ribosomal subunits are transported out of the nucleus and into the cytoplasm, 
where they then combine with processed mRNA transcripts. Specifically, the 40S subunit first 
binds with translation initiation factors and an mRNA transcript, which then facilitates the 
binding of the 60S subunit [3]. This constitutes the formation of a fully functional ribosome, 
which is the cellular translation machinery that is responsible for catalyzing protein synthesis [4]. 
Given the multitude of proteins required for normal cell function and survival, the role of 
ribosomes as the cellular translation machinery makes them indispensable for cellular growth. As 
such, the critically important roles that the nucleolus plays in ribosomal biogenesis can have a 
drastic impact on the capacity of the cell to grow [2]. Additionally, the nucleolus has been 
attributed many roles in the maintenance of cellular homeostasis and its dysfunction has been 
linked to various pathologies [5]. While in eukaryotes RNA polymerase (pol) II is responsible 
for the transcription of genes encoding proteins, RNA pol I is responsible for the transcription of 
rRNA-encoding genes in the nucleolus [6, 37]; therefore, RNA pol I transcriptional activity 
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serves as an important regulator of ribosomal biogenesis and thus enables protein synthesis and 
cellular growth [7]. Activity of RNA pol I, in turn, is closely regulated by multiple biochemical 
pathways to adjust ribosomal biogenesis according to cellular demands [7]. Generally speaking, 
conditions that are detrimental to cell growth (such as lack of growth factors or inhibition of 
protein synthesis) result in a down-regulation of RNA pol I [30]. Conversely, RNA pol I is up-
regulated to increase rRNA synthesis by the presence of neurotrophic factors, mitogenic signals, 
and favorable environmental conditions. Specifically, as one of its final targets, the extracellular 
signal-related kinase (ERK) pathway phosphorylates transcription initiation factor 1A (TIF-IA), 
which promotes the association of RNA pol I with rDNA gene promoters in rRNA synthesis 
[31]. In sum, RNA pol I tightly links cellular growth to changes in environmental conditions by 
determining the level of ribosome production [30–32].  
 
Given its role in the regulation of RNA pol I activity, TIF-IA was selected as a target for 
shRNA-mediated inhibition in this experiment. More than two decades ago, TIF-IA was found to 
control the growth-dependent regulation of rRNA synthesis in mice by responding to 
extracellular signals [38]. More broadly, it was found that TIF-IA is the mammalian functional 
homolog of the yeast factor Rrn3p, both of which “activate” RNA pol I, making it competent for 
transcription initiation [39, 40]. Specifically, this activation is achieved by direct association of 
TIF-IA with RNA pol I to form a transcriptionally active holoenzyme that is able to bind to the 
rDNA promoter and initiate transcription in the presence of auxiliary cofactors, including the 
selectivity factor SL-1 (also called TIF-IB) and upstream binding factor (UBF) [38]. Different 
signaling pathways are believed to be responsible for the ability of TIF-IA to respond to 
extracellular signals and regulate cell growth and proliferation, especially via ERK- and mTOR 
(mammalian target of rapamycin)-mediated modulation of the phosphorylation state of TIF-IA 
[31, 32]. Further regulation includes the action of the Akt pathway, which stabilizes TIF-IA, 
triggers its nucleolar translocation, and augments its interaction with RNA pol I [41]. Also, in 
connection with TIF-IA, this project takes advantage of the nucleolar phosphoprotein B23 (also 
known as numatrin, nucleophosmin, and NPM1) [18]. Given its localization in the nucleolus and 
its association with pre-ribosomal particles, B23 is an established nucleolar marker [18, 24]. As 
such, B23 dispersion serves as an indicator of nucleolar disruption and, thus, successful shTIF-
IA inhibition of RNA pol I activity. In sum, as the primary regulator of RNA pol I-driven rDNA 
transcription, TIF-IA activity is of obvious importance for ribosomal biogenesis. 
 
Despite shared transcriptional and translational processes underlying general cellular growth, 
different cells types demonstrate different patterns of development based on their specifically 
determined functions. Neurons are post-mitotic cells that no longer divide but continue to grow. 
Specifically, this growth consists of the development and elongation of neurites, including axons 
and dendrites. This neurite development – specifically with hippocampal neuron cultures – has 
been thoroughly studied in vitro, elucidating a process that can be broken down into five 
characteristic stages: within hours of adhering to the substrate, Stage 1 cells develop many small, 
motile, peripheral extensions known as lamellipodia; during Stage 2 the lamellipodia extend and 
become minor processes after about one day in vitro (DIV 1); within DIV 1-2, Stage 3 sees the 
particularly pronounced outgrowth of a single minor process, which forms a single major 
process. This major process continues its rapid growth, becoming a clearly identifiable axon 
between DIV 3-7. Significant dendritic outgrowth begins during Stage 4 around DIV 4, but the 
dendrites remain morphologically and biochemically distinct from the singular axon. [23]  
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However, such extensive morphological development of neurons involves a marked increase in 
cell volume and surface area. These increases necessarily require various macromolecules to 
support membranous and cytoskeletal expansions. An important study by Jareb and Banker 
demonstrated how axonal growth is differentially affected by inhibition of the supply of these 
macromolecules in rat hippocampal neurons at 18 hours after plating: disruption of the supply of 
Golgi-derived vesicles by treatment with brefeldin A inhibited axonal growth within one hour, 
showing the importance of lipid membrane components; cycloheximide (CHX)-mediated 
disruption of protein synthesis also significantly inhibited axonal growth, but only after six 
hours; and actinomycin D, a general RNA synthesis inhibitor, also inhibited axonal growth after 
nine hours [42] (Figure 1). The selected timeframe of about 18-30 hours after plating roughly 
corresponds to the aforementioned Stage 3 (DIV 1-2) in which robust axon growth begins [23]. 
Therefore, the supply of lipids, RNA, and proteins to the developing axon appear to be crucial 
for growth during this early phase of elongation. Of particular interest for this work is the 
necessity of protein synthesis for axonal growth, given that ribosomal biogenesis ultimately 














Given the importance of protein synthesis for axonal development, proper regulation becomes 
crucial. The protein kinase mTOR has been identified as a key regulator of cellular growth via its 
regulation of protein synthesis and the translation machinery [29]. In particular, PI3K 
(phosphatidylinositol 3-kinase)/mTOR signaling regulates TIF-IA activity [7,32]. In addition to 
affecting numerous other downstream targets, the role of mTOR in recruitment of ribosomes to 
mRNA has been linked to its phosphorylation of RPS6, a functional component of ribosomes 
[12]. The aforementioned interlacing signaling pathways provide for careful control of protein 
synthesis. Nevertheless, the location of this protein synthesis within the neuron has been debated 
for decades. While dendrites have long been known to contain ribosomes and undergo local 
protein synthesis, the same was not thought to occur in axons [28]. In fact, ribosomes were 
thought to be excluded from axons; it was believed that axoplasmic proteins were actually 
produced in the cell body and slowly transported to their particular destination(s) in the axon [33, 
and references contained therein]. However, a recently growing body of evidence has indicated 
that axons also possess ribosomes and rely on local protein synthesis for growth and directional 
responses [34 and references contained therein]. Indeed, studies have shown that ribosomes exist 
within periaxoplasmic ribosomal plaques (PARPs) distributed across the length of the axon, and 
that myosin and kinesin motor proteins play a role in this ribosomal trafficking and distribution 
[43]. Local protein synthesis in axons is thought to be necessary for expedient control of the 
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local proteome, including correct localization of axonal proteins, allowing the growth cone to 
quickly respond to environmental stimuli, and to avoid macromolecular crowding caused by 
protein storage [35 and references contained therein]. Interestingly, it has been shown that 
neurite outgrowth is resistant to incomplete inhibition of protein synthesis by CHX; this 
resistance is attributed to a concurrent decrease in the rate of protein degradation that parallels 
the decrease in protein synthesis [36]. 
 
Observations of nucleolar morphology in different regions of the nervous system have provided 
evidence that increased ribosomal biogenesis – as indicated by dynamic nucleolar activity and 
reorganization – is directly linked to neuronal growth [8]. Indeed, Dr. Hetman’s lab has 
demonstrated that experimental knockdown of TIF-IA – a coactivator of RNA pol I – in rat 
hippocampal neuron cultures inhibits brain-derived neurotrophic factor-induced (BDNF) neurite 
growth, although not overall protein synthesis [7]. These results demonstrate the dependence of 
nervous system development on the nucleolar transcriptional activity of RNA pol I, indicating 
the importance of the nucleolus for neural cell growth. Because general protein synthesis was not 
reduced in experiments with cells from DIV 2-3, these morphogenetic requirements for neuritic 
growth in this early phase of development cannot be accounted for simply in terms of changes in 
overall capacity for translation. By contrast, when RNA pol I was inhibited on DIV 6-8, 
translational capacity was clearly reduced [Slomnicki and Hetman, unpublished observations]. 
Stemming from this research on the role of RNA pol I in neurite outgrowth, the Hetman lab is 
now investigating the role of ribosomal biogenesis in neurite outgrowth via short hairpin RNA 
(shRNA) knockdown of TIF-IA and various ribosomal proteins, including RPS6, RPL4, and 
RPS14. Currently unpublished data from Dr. Hetman’s lab has shown that shRNA-mediated 
knockdown of TIF-IA, RPL4, RPS14, and RPS6 significantly reduced dendritic growth in later 
stages from DIV 6-9; this indicates the importance of pol I activity and ribosomal biogenesis in 
dendritic growth [Slomnicki et al. In preparation]. However, these experiments did not involve 
axons, which, unlike dendrites, are uniquely neuronal structures; therefore, it remains to be tested 
whether or not shRNA knockdown of TIF-IA and/or ribosomal proteins will similarly impact 
axonal growth. 
 
As integral components of functioning ribosomes, ribosomal proteins are important for protein 
synthesis and, thus, cellular growth. For this experiment, RPS6 was selected as the ribosomal 
target for shRNA knockdown to determine the effect that this would have on axonal growth. 
RPS6 was discovered in 1974 in connection with liver regeneration [10]. RPS6 is a ribosomal 
protein consisting of 249 amino acids, including five known phosphorylation sites – which are 
evolutionarily conserved in metazoans – at clustered residues in the C-terminal region of the 
protein: Ser235, Ser236, Ser240, Ser244, and Ser247 [11]. Since its discovery, RPS6 has been one of 
the most extensively researched ribosomal proteins, largely due to the fact that it was the first 
ribosomal protein to be known for its capacity for inducible phosphorylation [12]. In terms of its 
canonical role as a ribosomal protein, RPS6 is a component of the small 40S subunit of 
eukaryotic ribosomes; it is located at the interface of the 40S subunit with the 60S subunit, where 
it interacts with initiation factors, mRNA, and tRNA [13]. As such, it appears that RPS6 
functions in mRNA binding, and so phosphorylation of RPS6 may help to regulate translation 
[12]. With respect to phosphorylation, RPS6 is included within the category of S6 kinase (S6K) 
substrates [12]. As such, it was previously suggested that RPS6 phosphorylation may regulate 
initiation of translation and inclusion of ribosomes in polysomes; however, experiments with 
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RPS6P-/- knock-in mice liver cells (with phosphorylation prevented at all aforementioned serine 
residues) have shown the same proportion of ribosome recruitment into polysomes as in the liver 
cells of wild-type mice. Indeed, in comparison with the wild-type mice, protein synthesis levels 
in the knock-in mice were actually higher, suggesting that RPS6 phosphorylation down-regulates 
protein synthesis in at least liver cells [12]. Evidence shows that RPS6 phosphorylation plays 
other key roles, such as regulating translation of 5’ terminal oligopyrimidine (TOP) mRNA 
tracts. Additionally, elevated RPS6 levels were discovered in primary diffuse large B-cell non-
Hodgkin lymphoma samples with excessive cellular proliferation, whereas genetic treatment 
with shRPS6 led to a reduction in cell proliferation [14]. Given the potential novel roles that 
RPS6 may play, further investigation is needed to discern the mechanism by which RPS6 
expression may regulate axon growth. 
	  
RESESARCH PROBLEM          
Currently unpublished data from Dr. Hetman’s lab has shown that shRNA-mediated knockdown 
of TIF-IA and various ribosomal proteins (RPL4, RPS14, and RPS6) significantly reduced 
dendritic growth [Slomnicki et al. In preparation]. While working in Dr. Hetman’s lab during the 
previous academic year, we sought to continue this line of research and investigate whether a 
similar effect is observed in growth of axon. Because axons are a uniquely neuronal appendage, 
the effects that such disruptive knockdowns have on axons are of particular importance: the 
unique ability of axons to successfully elongate to great lengths underlies the structure and 
connectivity of a healthy nervous system. Therefore, this project seeks to investigate the 
importance of ribosomal biogenesis and nucleolar activity for axon development. In order to do 
this, ribosomal biogenesis was partially inhibited via shRNA knockdown of RPS6, and nucleolar 
function was disrupted by strong inhibition of RNA pol I activity via shTIF-IA knockdown. 
 
EXPERIMENTAL PROCEDURES         
Materials: The following antibodies and reagents were obtained from commercial sources: 
reagents included BDNF (Alomone, Haifa, Israel) and Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA); primary antibodies included rabbit anti-GFP (MBL; 1/1000) and mouse anti-
B23/NPM1 (Sigma; 1/750); and secondary antibodies included Alexa Fluor 488 goat anti-rabbit 
IgG (Invitrogen, 1/300) and Alexa Fluor 555 goat anti-mouse IgG (Invitrogen, 1/300). 
 
Plasmid Preparation: Back transformation allowed for the extraction of the desired pSUPER 
plasmid vector (OligoEngine) from Escherichia coli bacteria: the cells were subjected to a 
membrane dissolving chemical and centrifuged, and the resulting supernatant containing the less 
dense plasmid DNA was collected. A plasmid mini-preparation kit (Qiagen) was then used to 
chromatographically isolate the DNA, utilizing various buffers to remove contaminants such as 
RNA, nucleases, and carbohydrates. Following workup, plasmid DNA sample purity was 
determined using a NanoDrop spectrophotometer. 
 
Neuron Culture & Transfection: Hippocampal neurons were isolated from newborn Sprague-
Dawley rats (Harlan) at postnatal day zero (P0), as described previously [15]. Briefly, 
hippocampi were dissected and digested using papain, followed by a trypsin inhibitor; the 
hippocampi were then triturated in Basal Medium Eagle (BME) supplemented with 10% heat-
inactivated bovine calf serum (Hyclone). Finally, the hippocampal neurons were plated at a 
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density of 0.2 × 106 per well in a 24-well plate in Neurobasal medium containing 2%-B27 
nutrition supplement (Invitrogen), 1 mM L-glutamine, 100 units/mL penicillin, and 0.1 mg/mL 
streptomycin. Cells were plated onto poly-D-lysine- and laminin-coated 12 mm diameter plastic 
coverslips that were produced in the lab from the electron microscopy-grade myalar masks 
(Electron Microscopy Sciences). Half of the media was changed every other day. At one day in 
vitro (DIV 1) neurons were transiently cotransfected with expression plasmids for GFP (0.1 µg 
of plasmid DNA/2 × 105 neurons) as a transfection marker, and either control Renilla luciferase 
shRNA (shLuc), shTIF-IA, or shRPS6 (0.4 µg of plasmid DNA/2 × 105 neurons), using 
Lipofectamine 2000 according to standard manufacturer protocol. On DIV 2 the cells were also 
treated with either human recombinant BDNF (20 ng/mL) dissolved in the vehicle solution of 
0.1% BSA/PBA, or the vehicle alone, for a further 24 hours, followed by fixing cells with 4%-
formaldehyde solution after immunostaining on DIV 3-4. 
 
Immunostaining: All cultured neurons were stained after 10-minute fixation in 4% PFA with 4% 
sucrose, followed by washing with PBS. GFP staining was performed using primary rabbit anti-
GFP antibody (1/1000), followed by secondary Alexa Fluor 488 goat anti-rabbit IgG (1/300). 
B23 staining was performed using primary mouse anti-B23/NPM1 antibody (1/750), followed by 
secondary Alexa Fluor 555 goat anti-mouse IgG (1/300). In all cases, standard staining protocols 
were followed. Following immunostaining, cells were counterstained with 2.5 µg/mL of the 
DNA dye Hoechst 33258 in order to visualize nuclear morphology. After washing in PBS, 
coverslips were mounted on coverslips in glycerol gelatin (Sigma) containing p-phenyldiamine 
glycerol. 
 
shRNA Construct Generation & Validation: Two different shRPS6 constructs (designated as 
“shRPS6.1” and “shRPS6.2”) and three different shTIF-IA constructs (used together, designated 
as “shTIF-IA”) had been previously generated by analyzing each mRNA sequence using shRNA 
design software (Ambion.com) and off-target prediction software (sonnhammer.sbc.su.se) as 





TIF-IA#3: 5’-gatccccgtgttctgctacaccatcattcaagagatgatggtgtagcagaacactttttggaaa-3’) together with 
their complementary counterparts, annealed and sub-cloned into a pSUPER vector digested with 
BglII and HindIII [26; Slomnicki et al. In preparation]. Within the shRPS6 experiment, the first 
two groups consisted of the separated S6#1 (shRPS6.1) and S6#2 (shRPS6.2) sequences, 
respectively. In order to control for potential off-target effects, the third shRPS6 experimental 
group consisted of both shRPS6 constructs (S6#1 and S6#2) mixed together in halved, 
proportionate amounts (0.2 µg of plasmid DNA/2 × 105 neurons of both constructs together). The 
control group was transfected with shLuc, which targets the Renilla luciferase mRNA sequence 
(5′-caaaggaaacggatgataa-3’) [26]. Validation of constructs and confirmation of successful RPS6 
and TIF-IA knockdown was previously demonstrated [26; Slomnicki et al. In preparation]. 
 
Image Acquisition & Morphometric Analysis: Fluorescence microscopy (Zeiss Observer.Z1 
inverted microscope) was used to obtain images from stained and fixed slides. Unfragmented 
neurons were visualized with GFP immunostaining under a 10x objective lens. AxioVision 
software was used to obtain black-and-white TIFF image files. Morphometric analysis of TIFF 
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images was carried out using the program Neuron Studio to trace axon paths [44]. Tracing files 
generated by Neuron Studio were then analyzed in the MATLAB program (MathWorks) using 
custom scripts that calculated the following key axonal parameters; total axon length, longest 
axon path and number of branches  
 
Quantification of shTIF-IA Inhibition: Nucleolar dispersion was assessed in shTIF-IA-transfected 
neurons by assessing B23 immunostaining: control shLuc cells and cells with unsuccessful 
shTIF-IA transfection presented with dense, red, brightly stained B23-positive foci indicative of 
intact nucleoli; cells with successful shTIF-IA transfection lacked these dense B23-positive foci 
and instead presented a more diffuse signal, indicating nucleolar dispersion. Cells not indicating 
this nucleolar dispersion were not considered for imaging, tracing, or statistical analysis. 
 
Statistical Analysis: Statistical analysis of the data involved using a two-way analysis of variance 
(ANOVA) in conjunction with post hoc Fisher least significant difference tests. 
 
EXPERIMENTAL GROUPS          
 
shRPS6	  Experiments	  
Control	  Group	  -­‐	  
shLuc	  
Experimental	  Group	  #1	  -­‐	  
shRPS6.1	  
Experimental	  Group	  #2	  -­‐	  
shRPS6.2	  
Experimental	  Group	  #3	  -­‐	  
shRPS6.1	  &	  shRPS6.2	  
Vehicle	   Vehicle	   Vehicle	   Vehicle	  
Vehicle	  +	  BDNF	   Vehicle	  +	  BDNF	   Vehicle	  +	  BDNF	   Vehicle	  +	  BDNF	  
 
shTIF-­‐IA	  Experiments	  
Control	  Group	  -­‐	  shLuc	   Experimental	  Group	  -­‐	  shTIF-­‐IA	  
Vehicle	   Vehicle	  
Vehicle	  +	  BDNF	   Vehicle	  +	  BDNF	  
 
RESULTS             
First, we set out to determine the effects of transient shRNA knockdown of RPS6 on axon 
morphology in rat hippocampal neuron cultures. Cultures of transiently transfected and 
immunostained hippocampal neurons were fixed on slides, after which microscopic images were 
taken using a GFP filter. Slides were coded to avoid experimenter bias, and axons were 
consistently identified based on characteristic appearance and length [Figure 2]. Following 
morphometric analysis with NeuronStudio and MATLAB software, we primarily focused on 
three axonal parameters: total length, longest path, and number of branches. 
 
For all control and experimental groups involving shRPS6, each group’s data represents the 
mean ± S.E.M. for a total of at least 39 randomly selected neurons from two independent 
experiments. Under baseline shLuc control conditions, axons demonstrated the following level of 
growth and complexity: total axon length of 809 ±45 µm, longest axon path of 442 ±17 µm, and 
6.78 ±0.67 axonal branches (all data presented as means ± S.E.M.) [Figures 3–5]. Upon BDNF 
stimulation, the shLuc controls did not experience any significant neurotrophic boost of axon 
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development compared to the baseline vehicle treatment: total axon length of 820 ±40 µm, 
longest axon path of 473 ±20 µm, and 6.93 ±0.65 axonal branches (compared to baseline, all 



























Of the three parameters, shRNA treatment only yielded statistically significant differences in 
total axon length. Total length was reduced (albeit not drastically) in all shRPS6 experimental 
groups except for the mixed construct group that was exposed to BDNF. Compared to the shLuc 
control baseline, decreases were seen with mixed shRPS6 constructs (809 ±45 vs. 587 ±25 µm, p 
< 0.001), shRPS6.1 (809 ±45 vs. 712 ±34 µm, p <0.05), and shRPS6.2 (809 ±45 vs. 680 ±33 µm, 
p < 0.01); compared to the shLuc control with BDNF treatment, decreases were only seen with 
shRPS6.1 (820 ±40 vs. 667 ±26 µm, p < 0.01) and shRPS6.2 (820 ±40 vs. 699 ±30 µm, p < 
0.05), but not with mixed shRPS6 constructs (820 ±40 vs. 773 ±33 µm, NS)  [Figure 3].  
The results for longest path and number of branches did not indicate a consistent, significant 
effect on axonal growth. Compared to the shLuc control baseline, the longest axon path was 
decreased by mixed shRPS6 (442 ±17 vs. 370 ±15 µm, p < 0.01), but was unaffected by 
shRPS6.1 (442 ±17 vs. 445 ±20 µm, NS) and shRPS6.2 (442 ±17 vs. 401 ±17 µm, NS); 
compared the shLuc control with BDNF, longest axon path saw no effect with mixed shRPS6 
(473 ±21 vs. 460 ±15 µm, NS), a decrease with shRPS6.1 (473 ±21 vs. 416 ±15 µm, p < 0.05), 
and no effect with shRPS6.2 (473 ±21 vs. 443 ±18 µm, NS) [Figure 4]. Compared to the shLuc 
control baseline, there was no effect on number of axonal branches with mixed shRPS6 
(6.78 ±0.67 vs. 5.28 ±0.46, NS), shRPS6.1 (6.78 ±0.67 vs. 7.30 ±0.84, NS), or shRPS6.2 
Figure 2: Per the characteristic stages of neurite outgrowth for hippocampal neuron cultures, axons grow 
much more quickly than dendrites; therefore, by DIV 3-4, their length generally makes axons easy to 
distinguish from the shorter dendrites [23]. Thus, axons were identifiably distinct due their relatively sizable 
lengths (as compared to smaller dendrites, which remained clustered closely around the cell body).  
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(6.78 ±0.67 vs. 5.48 ±0.51, NS); compared to the shLuc control with BDNF, no effect was seen 
for mixed shRPS6 (6.93 ±0.65 vs. 6.00 ±0.55, NS) or shRPS6.1 (6.93 ±0.65 vs. 6.13 ±0.57, NS), 
but there was a decrease with shRPS6.2 (6.93 ±0.65 vs. 5.08 ±0.58, p < 0.05) [Figure 5]. 
  
** 





























Figure 4: No consistent, 
significant decrease of 
longest axon path was 
observed after transient 
transfection with all shRPS6 
constructs, with the exception 
of the baseline mixed shRPS6 
and the BDNF-treated 
shRPS6.1. Overall, there is 
no consistent pattern of 
decrease. Data are means, 
with error bars indicating 
S.E.M. *, p < 0.05; **, p < 
0.01; NS, p > 0.05. 
Figure 3: Decrease in total 
axon length after transient 
transfection at DIV 1 with all 
shRPS6 constructs, but most 
consistently for the separated 
constructs. Compared to 
shLuc controls, this decrease 
was observed with and 
without BDNF treatment for 
all experimental groups 
except mixed shRPS6 
constructs (where length 
decreased significantly only 
in the absence of BDNF). 
Data are means, with error 
bars indicating S.E.M. *, p < 
0.05; **, p < 0.01; ***, p < 
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Also, data from axonal experiments with shTIF-IA were examined by selecting specifically for 
cells that demonstrated complete dispersion of the immuostained nucleolar marker B23, which 
normally remains bound to nucleolar rRNA [18, 24]. By selecting for cells lacking distinct B23-
immunostained nuclei, we were able to ascertain exactly which cells had indeed experienced 
shTIF-IA-mediated inhibition of pol I (and thus inhibition of de novo ribosome synthesis) 
[Figure 6]. For all shLuc control groups in the shTIF-IA experiment, the data represents the 
mean ± S.E.M. for a total of at least 39 randomly selected neurons from two independent 
experiments. For all shTIF-IA experimental groups, the data represents the mean ± S.E.M. for a 
total of at least 19 randomly selected neurons (among those that demonstrated B23 dispersion) 























Figure 6: Immunostaining with fluorescence microscopy allowed for selection of only those neurons that 
demonstrated dispersion of the nucleolar phosphoprotein marker B23 and, thus, successful transfection by 
shTIF-IA. In shLuc control cells, B23 staining resulted in small, dense, bright red granules (nucleoli) within a 
larger, less dense, dull red region (nucleus). In shTIF-IA cells, B23 staining resulted in the absence of any of 
the smaller, dense, bright red granules, thereby indicating nucleolar dispersion.  
Figure 5: No consistent, 
significant decrease of 
number of axonal branches 
was observed after transient 
transfection with all shRPS6 
constructs, with the exception 
of the BDNF-treated 
shRPS6.2. Overall, there is 
no consistent pattern of 
decrease. Data are means, 
with error bars indicating 
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Under baseline shLuc control conditions, axons demonstrated the following level of growth and 
complexity: total axon length of 558 ±28 µm, longest axon path of 382 ±13 µm, and 4.18 ±0.45 
axonal branches. Once again, BDNF treatment of shLuc controls failed to stimulate increased 
growth compared to the baseline treatment: total axon length of 617 ±32 µm, longest axon path 
of 408 ±25 µm, and 5.03 ±0.70 axonal branches (compared to baseline, all three parameters NS, 
p > 0.05). Within baseline and BDNF treatment groups for each parameter, shTIF-IA did not 
result in a statistically significant decrease for any parameters, with the only exception being a 
decrease in branch ratio under BDNF treatment. Compared to the baseline shLuc control, shTIF-
IA treatment produced no change in total axon length under baseline conditions (558 ±28 vs. 
589 ±29 µm, NS) or BDNF treatment (617 ±32 vs. 512 ±33 µm, NS) [Figure 7]; similarly, 
longest axon path saw no change under baseline conditions (382 ±13 vs. 341 ±16 µm, NS) or 
BDNF treatment (408 ±25 vs. 334 ±19 µm, NS) [Figure 8]; and the number of axonal branches 
saw no change under baseline conditions (4.18 ±0.45 vs. 5.39 ±0.67 µm, NS) but decreased under 
BDNF treatment (5.03 ±0.70 vs. 3.53 ±0.48 µm, p < 0.05) [Figure 9]. 
 
All in all, these data indicate that shRPS6 did result in some significant decreases across all 
parameters of axon growth, though overall the effects were relatively small and somewhat 
inconsistent. The shTIF-IA produced essentially no significant decrease of axon growth, with the 
only exception being the decrease in number of axonal branches under BDNF treatment. 
Therefore, ribosomal biogenesis does not appear to be of major importance for axon growth at 











Figure 7: No significant 
decrease in total axon 
length after transient 
transfection with shTIF-IA 
observed between either 
baseline groups or BDNF-
treated groups. Data are 
means, with error bars 

























Figure 8: No significant 
decrease in longest axon 
path after transient 
transfection with shTIF-IA 
observed between either 
baseline groups or BDNF-
treated groups. Data are 
means, with error bars 
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DISCUSSION            
Initially, our hypothesis 
held that shRNA-mediated 
knockdown of TIF-IA and 
RPS6 would result in a 
decrease in axonal growth 
due to direct inhibitory 
effects on RNA pol I 
activity and ribosomal 
biogenesis. Ultimately, 
however, our data indicate 
that this hypothesis was 
incorrect. Despite 
antagonizing TIF-IA and 
RPS6 – both of which play 
important roles in ribosome 
production – it appears that 
pre-existing ribosomes are 
sufficient for initial axonal 
elongation [Figure 10]. 
However, the duration of this pre-existing ribosome supply would presumably be temporally 
limited by the 6-day half-life of cytoplasmic ribosomes in the rat brain [9]. Thus, given more 
time, ribosomal biogenesis inhibition would be expected to affect translation and axonal growth. 
Aside from the hypothetical aspect regarding pre-existing ribosome supply, this schematic also 
assumes the implicit necessity of protein synthesis for axonal growth during this stage; this 
assumption is supported, however, by previously mentioned research showing that CHX-
mediated disruption of protein synthesis did indeed inhibit axonal growth during DIV 1-2 [42]. 
 
To be sure, shRNA knockdown of RPS6 did have a consistent, slight inhibitory effect on total 
axonal length (but not on axon path or number of axonal branches) during the initiation phase of 
Figure 9: Decrease in 
number of branches after 
transient transfection with 
shTIF-IA observed 
between BDNF-treated 
groups, but not between 
baseline vehicle-treated 
groups. Data are means, 
with error bars indicating 
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axonal development. Yet, while the decreases in total axon length for the shRPS6 constructs 
were statistically significant, the effect was relatively small and not entirely consistent. These 
results were corroborated by our experiments with shTIF-IA when B23 dispersion was taken into 
consideration to assure shTIF-IA transfection and inhibition of rRNA transcription: the data did 
not show a consistent, significant decrease in any of the three morphogenetic parameters. Taken 
together, these complementary findings indicate that ribosome biogenesis and RNA pol I activity 
are not important for axonal growth during the initiation phase of axonal development. 
When interpreting these results, the slight inhibitory effect of shRPS6 could be attributed to the 
role of RPS6 in ribosomal biogenesis, but could also potentially indicate that RPS6 has a non-
canonical role other than being a structural and functional ribosome component. Once again, 
future experiments would be necessary to obtain more evidence. The relatively modest 
magnitude of the observed inhibitory effects, however, call into question the utility and 
effectiveness of further experiments, such as with phosphomutants to block RPS6 
phosphorylation.  
 
Interestingly, there is no significant difference in the results for axon morphological parameters 
between the baseline vehicle groups and the BDNF treatment groups. Despite the fact that the 
vehicle treatment ideally represents baseline growth while BDNF treatment represents 
neurotrophically-enhanced growth, it appears that BDNF is not significantly increasing axon 
elongation during this stage. Given that the cells were fixed by DIV 3-4, this lack of BDNF 
stimulation can likely be explained by the considerably robust level of axon growth around DIV 
2 [23]; treatment with BDNF does little to increase this already robust, early growth.  
 
Future research would include an investigation of the importance of ribosomal biogenesis and 
pol I activity during later phases of axonal development. Presumably, both prolonged depletion 
of ribosomes and nucleolar disruption would result in a more extreme deficit during later phases. 
As such, it is probable that inhibition of ribosomal biogenesis (via ribosomal protein knockdown) 
and inhibition of pol I activity (via TIF-IA knockdown) during later phases would result in even 
more pronounced inhibition of axonal growth. Conducting experiments of this nature, however, 
is difficult. Such experiments would require waiting until at least DIV 6-9, at which point the 
axons grow to unwieldy lengths and present problems for tracing and morphometric analysis. 
 
Within a broader context, this line of research aims to elucidate the role of ribosomal biogenesis 
in healthy nervous system development at the cellular level. A relatively neglected field of study 
has been the intrinsic mechanisms underlying neuronal development, with much emphasis being 
placed instead on stimulated or altered growth and pathological growth problems. As such, this 
research on rRNA and ribosomal production complements prior research on the importance of 
biosynthesis of other macromolecules for normal neuron development during this initial growth 
phase, including the processes of protein synthesis, lipid synthesis, and general transcription. 
Additionally, it explores how dysfunctional ribosomal biogenesis or irregular neurite 
morphogenesis may contribute to the pathogenesis of nervous system disorders. Generally, it is 
expected that a lack of mature, functional ribosomes – which are responsible for protein 
translation and, in turn, cell growth – would be lethal during embryonic development. However, 
a recently investigated class of rare, genetic diseases of ribosome function and biogenesis – 
referred to as “ribosomopathies” – has shown this expectation is not always true [19, 20]. Among 
the causes for these ribosomopathies is a deficiency of ribosomal proteins: Diamond-Blackfan 
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anemia is caused by congenital mutations in the genes for RPS19 and other ribosomal proteins, 
and 5q– syndrome is brought on in part by a haploinsufficiency of RPS14 [20]. As a more 
neurologically relevant example, one study has provided evidence that links a decline in protein 
synthesis both to a decline in ribosome precursors and to high levels of oxidative damage to 
ribosomal-associated RNA in the brains of patients with Alzheimer’s disease [21]. In addition, 
mutations in the gene for RPL10 have been identified as the potential causal agents of the 
cognitive malfunction seen in various cases of autism [22]. Finally, another recent study has 
identified RPS15 as a mediator of the LRRK2-induced neurodegeneration seen in Parkinson’s 
disease [25]. As the involvement of dysfunctional ribosomal biogenesis and neurite 
morphogenesis in various diseases becomes increasingly apparent, our knowledge of these 
cellular processes will continue to grow in importance. 
 
In conclusion, neither shRPS6 nor shTIF-IA knockdown produced a consistent, meaningful 
inhibitory effect on axon growth. It can be argued that the lack of a large inhibitory effect 
following shRPS6 treatment is attributable to the fact that such shRNA knockdown is only able 
to bring about an incomplete knockdown of RPS6, which is merely a single ribosomal 
component. Consequently, the shTIF-IA experiment becomes increasingly important because it 
avoids this issue: selecting for cells that only demonstrated complete B23 dispersion allowed for 
the incorporation of only those cells whose nucleoli had been disrupted. Because nucleoli are 
essentially brought into existence by their very “act of building a ribosome” [27], this lack of 
visible nucleoli indicates that the entire process of ribosomal biogenesis has been disrupted. 
Therefore, combining the results from these two experiments provides convincing evidence that 
nucleolar RNA pol I activity (and the nucleolus-based process of ribosomal biogenesis) are of 
minor importance to axon growth during this early phase of development. As an explanation for 
this ability of axons to continue growing in the face of such inhibition, it is important to consider 
the fact that shTIF-IA was shown to not disrupt translation specifically during the timeframe of 
DIV 1-3 in which these experiments were conducted; previous experiments in which both 
dendrite growth and translational capacity were diminished by shTIF-IA were conducted later 
during DIV 6-9 [Slomnicki and Hetman, unpublished observations]. With this consideration in 
mind, it appears that the various effects of ribosomal biogenesis inhibition on neurites can be 
explained by differential modulation of protein synthesis, which appears to be essential for axon 
growth [42]. Furthermore, considering the 6-day half-life of cytoplasmic ribosomes in the rat 
brain and the robustness of cellular growth in this early stage [9, 23], the cell is able to maintain 
protein synthesis and axon development despite experimental disruption of de novo ribosomal 
biogenesis. 
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